Hayes D, Sauerbrei W, McShane L
Br J Cancer. 2022; 128(3):443-445.
PMID: 36476656
PMC: 9938190.
DOI: 10.1038/s41416-022-02046-4.
Kuo W, Tseng L, Chang C, Chen C, Cheng M, Cheng H
Diagnostics (Basel). 2021; 11(8).
PMID: 34441396
PMC: 8392504.
DOI: 10.3390/diagnostics11081460.
Yu Z, Song M, Chouchane L, Ma X
Cancers (Basel). 2021; 13(13).
PMID: 34208889
PMC: 8268362.
DOI: 10.3390/cancers13133276.
Hunter N, Kilgore M, Davidson N
Clin Cancer Res. 2020; 26(21):5543-5545.
PMID: 32859655
PMC: 8791049.
DOI: 10.1158/1078-0432.CCR-20-2451.
Adnan N, Liu Z, Huang T, Ruan J
BMC Med Genomics. 2020; 13(Suppl 5):40.
PMID: 32241278
PMC: 7119280.
DOI: 10.1186/s12920-020-0676-3.
Effect of fraxetin on proliferation and apoptosis in breast cancer cells.
Liu G, Liu Z, Yan Y, Wang H
Oncol Lett. 2018; 14(6):7374-7378.
PMID: 29344176
PMC: 5755049.
DOI: 10.3892/ol.2017.7143.
Prognostic and predictive value of low estrogen receptor expression in breast cancer.
Bouchard-Fortier A, Provencher L, Blanchette C, Diorio C
Curr Oncol. 2017; 24(2):e106-e114.
PMID: 28490933
PMC: 5407873.
DOI: 10.3747/co.24.3238.
Detecting gene signature activation in breast cancer in an absolute, single-patient manner.
Paquet E, Lesurf R, Tofigh A, Dumeaux V, Hallett M
Breast Cancer Res. 2017; 19(1):32.
PMID: 28327201
PMC: 5361722.
DOI: 10.1186/s13058-017-0824-7.
Predicting Clinical Outcomes Using Molecular Biomarkers.
Burke H
Biomark Cancer. 2016; 8:89-99.
PMID: 27279751
PMC: 4896533.
DOI: 10.4137/BIC.S33380.
Data Requirements for Model-Based Cancer Prognosis Prediction.
Dalton L, Yousefi M
Cancer Inform. 2016; 14(Suppl 5):123-38.
PMID: 27127404
PMC: 4844301.
DOI: 10.4137/CIN.S30801.
Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A
Indian J Surg Oncol. 2016; 6(4):378-383.
PMID: 27065665
PMC: 4809839.
DOI: 10.1007/s13193-015-0449-1.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes.
Martei Y, Matro J
Breast Cancer (Dove Med Press). 2015; 7:337-43.
PMID: 26504408
PMC: 4603628.
DOI: 10.2147/BCTT.S91981.
Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data.
Jinks R, Royston P, Parmar M
BMC Med Res Methodol. 2015; 15:82.
PMID: 26459415
PMC: 4603804.
DOI: 10.1186/s12874-015-0078-y.
Diffusion magnetic resonance imaging in breast cancer characterisation: correlations between the apparent diffusion coefficient and major prognostic factors.
Belli P, Costantini M, Bufi E, Giardina G, Rinaldi P, Franceschini G
Radiol Med. 2014; 120(3):268-76.
PMID: 25096888
DOI: 10.1007/s11547-014-0442-8.
The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer.
Mohammed Z, McMillan D, Edwards J, Mallon E, Doughty J, Orange C
BMC Clin Pathol. 2013; 13(1):31.
PMID: 24274633
PMC: 4175483.
DOI: 10.1186/1472-6890-13-31.
Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.
Groenendijk F, Zwart W, Floore A, Akbari S, Bernards R
Breast Cancer Res Treat. 2013; 140(3):475-84.
PMID: 23912957
PMC: 3742961.
DOI: 10.1007/s10549-013-2648-1.
Circulating tumor cell detection during chemotherapy in patients with breast cancer is not associated with plasma homocysteine levels.
Yoshihara R, Teixeira B, Adami F, Kuniyoshi R, Alves B, Gehrke F
Tumour Biol. 2013; 34(5):2937-41.
PMID: 23686807
DOI: 10.1007/s13277-013-0856-2.
Gene expression profiling of breast cancer survivability by pooled cDNA microarray analysis using logistic regression, artificial neural networks and decision trees.
Chou H, Yao C, Su S, Lee C, Hu K, Terng H
BMC Bioinformatics. 2013; 14:100.
PMID: 23506640
PMC: 3614553.
DOI: 10.1186/1471-2105-14-100.
Pathway-based classification of cancer subtypes.
Kim S, Kon M, DeLisi C
Biol Direct. 2012; 7:21.
PMID: 22759382
PMC: 3485163.
DOI: 10.1186/1745-6150-7-21.
NT5E CpG island methylation is a favourable breast cancer biomarker.
Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A
Br J Cancer. 2012; 107(1):75-83.
PMID: 22653144
PMC: 3389412.
DOI: 10.1038/bjc.2012.212.
